Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $15.50.

Several brokerages recently weighed in on ACHV. Citizens Jmp began coverage on shares of Achieve Life Sciences in a research note on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 target price on the stock. Citigroup began coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They issued an “outperform” rating on the stock. Raymond James Financial reiterated a “strong-buy” rating on shares of Achieve Life Sciences in a report on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC acquired a new position in Achieve Life Sciences during the 1st quarter worth approximately $32,000. Manchester Financial Inc. lifted its position in shares of Achieve Life Sciences by 90.8% during the 2nd quarter. Manchester Financial Inc. now owns 46,224 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 22,000 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Achieve Life Sciences during the 2nd quarter worth $263,000. Simplify Asset Management Inc. grew its stake in shares of Achieve Life Sciences by 443.7% during the second quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock worth $2,677,000 after purchasing an additional 966,667 shares in the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in Achieve Life Sciences in the second quarter valued at $300,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Trading Up 7.6%

Shares of ACHV stock opened at $4.25 on Friday. Achieve Life Sciences has a 1-year low of $1.84 and a 1-year high of $6.03. The firm has a market cap of $226.23 million, a PE ratio of -3.08 and a beta of 1.82. The company has a 50-day moving average of $4.82 and a two-hundred day moving average of $3.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, analysts predict that Achieve Life Sciences will post -1.17 EPS for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.